Beam Therapeutics Inc. (BEAM) 8-K Current Report — March 5, 2026
Filed: March 5, 2026
Health Care
Biological Products, (No Diagnostic Substances)Beam Therapeutics Inc. (BEAM) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 1.02: Termination of a Material Definitive Agreement
Beam Therapeutics Inc. 8-K Mar 5, 2026 Event Analysis
Item 1.02 · Termination of a Material Definitive Agreement
- • Bio Palette License Agreement terminated March 2, 2026 due to Bio Palette's planned dissolution — no future payments owed by either party
- • Continuity secured: Kobe University standby license (signed Feb 9, 2026) activated, preserving BEAM's exclusive base editing patent rights
Other Beam Therapeutics Inc. 8-K Filings
Get deeper insights on Beam Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.